Apotex Adds New Patent Challenge In Boniva Dispute

Law360, New York (December 15, 2008, 12:00 AM EST) -- Stepping up its efforts to win approval for a generic form of Hoffmann-La Roche Inc.'s osteoporosis drug Boniva, Canadian drugmaker Apotex Inc. has challenged the validity of one of Roche's patents.

In an amended complaint filed Friday in the U.S. District Court for the District of New Jersey, Roche said that Apotex has filed a Paragraph IV certification notice with the U.S. Food and Drug Administration seeking to challenge its U.S. Patent Number 7,410,957.

In the original complaint, filed in August, Nutley, N.J.-based Roche alleged that...
To view the full article, register now.